Introducing Dx:Revenue - Precision Medicine Intelligence for Business Development Teams

LEARN MORE
Posts From the monthly archives: "April 2015"

  The challenges faced by oncologists in using biomarker-based tests were underlined in a recent article by Dr. Marcus Neubauer in OncLive. In recent posts in this blog I have focused on the challenges of interpreting genomic data, but Dr. Neubauer emphasizes two additional and highly relevant points. The first is that just selecting…(Read More)

FDA and CMS have just announced that the agencies are forming a joint task force to explore “areas where collaboration may realize greater oversight efficiency and produce the greatest benefit to patients, providers, and laboratories.” This is a laudable effort that should ensure a minimum of overlapping regulation. FDA has played a central role throughout…(Read More)

  A new method for prognosing ovarian cancer was recently described by researchers from the University of Utah. While I am particularly interested in precision medicine developments for ovarian cancer, as it is an especially under-served disease, I am not actually pointing out this development strictly for its positive connotations (positive though they are…(Read More)

An interesting recent article in Genetic Engineering News describes the challenges of making sense of biomarkers of unknown relevance that surface from whole genome sequencing (WGS). Such biomarkers are becoming common enough that there is even a name for them: the “incidentalome,” (drawing on the “incidentaloma” concept from radiology, and perhaps first coined in a…(Read More)

Having recently conducted an analysis of biomarker panels in FDA-approved tests, we are now beginning to analyze biomarker panels in laboratory-developed tests (LDTs). To my knowledge this is the first publicly available analysis of LDTs. Utilizing a proprietary data gathering and filtering tool, we pulled down the test menus from the public websites…(Read More)